Loading
A phase 3 trial of Aumolertinib in non-small-cell lung cancer and small-cell lung cancer, run by Jiangsu Hansoh Pharmaceutical Co., Ltd., now recruiting.
A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer is a phase 3 interventional study registered as NCT04951635 by Jiangsu Hansoh Pharmaceutical Co., Ltd., with 150 participants planned, started 2021-03-18 and due to reach its primary completion in 2024-07-15. Interventions recorded: Almonertinib, Placebo Almonertinib. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Aumolertinib, Hansoh Pharmaceutical, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer.
Shares Aumolertinib, Unresectable stage III non-small-cell lung cancer, EGFR-mutated non-small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Aumolertinib, Hansoh Pharmaceutical, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer.
Shares Aumolertinib, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Aumolertinib, EGFR-mutated non-small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Unresectable stage III non-small-cell lung cancer, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Aumolertinib, EGFR-mutated non-small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Aumolertinib, EGFR-mutated non-small-cell lung cancer, Small-molecule kinase inhibitors.